tiprankstipranks
Advertisement
Advertisement

REGN Stock Latest News

Regeneron price target lowered to $854 from $855 at Piper Sandler
The FlyRegeneron price target lowered to $854 from $855 at Piper Sandler
2d ago
REGN
Regeneron price target lowered to $730 from $788 at Morgan Stanley
PremiumThe Fly
Regeneron price target lowered to $730 from $788 at Morgan Stanley
3d ago
REGN
Regeneron price target lowered to $769 from $778 at Truist
PremiumThe Fly
Regeneron price target lowered to $769 from $778 at Truist
4d ago
REGN
Regeneron price target lowered to $696 from $707 at RBC Capital
PremiumThe Fly
Regeneron price target lowered to $696 from $707 at RBC Capital
4d ago
REGN
Regeneron price target lowered to $800 from $990 at HSBC
PremiumThe Fly
Regeneron price target lowered to $800 from $990 at HSBC
5d ago
REGN
Regeneron price target lowered to $750 from $785 at Cantor Fitzgerald
PremiumThe FlyRegeneron price target lowered to $750 from $785 at Cantor Fitzgerald
5d ago
REGN
FDA selects seven participants for PreCheck Pilot Program
Premium
The Fly
FDA selects seven participants for PreCheck Pilot Program
12d ago
LLY
AMRX
Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says
Premium
The Fly
Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says
12d ago
LLY
AMRX
Regeneron Expands Metabolic Footprint With New Phase 2a Fatty Liver Study
PremiumCompany Announcements
Regeneron Expands Metabolic Footprint With New Phase 2a Fatty Liver Study
15d ago
REGN
Regeneron’s New First-in-Human Eczema Drug REGN20423: Early Trial Progress and Investor Takeaways
PremiumCompany Announcements
Regeneron’s New First-in-Human Eczema Drug REGN20423: Early Trial Progress and Investor Takeaways
16d ago
REGN
Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital
PremiumThe Fly
Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital
19d ago
ABBV
APGE
Regeneron announces FDA, EMA accept cemdisiran submissions for review
PremiumThe Fly
Regeneron announces FDA, EMA accept cemdisiran submissions for review
19d ago
REGN
AbbVie bid for Apogee Therapeutics makes sense, says Wells Fargo
PremiumThe FlyAbbVie bid for Apogee Therapeutics makes sense, says Wells Fargo
19d ago
ABBV
APGE
‘A Solid Fit’: JPMorgan Backs AbbVie’s Potential $11B Apogee Acquisition
Premium
Market News
‘A Solid Fit’: JPMorgan Backs AbbVie’s Potential $11B Apogee Acquisition
19d ago
SNY
ABBV
Regeneron Advances First-in-Human Myeloma Combo Trial, Keeping Oncology Pipeline in Focus
Premium
Company Announcements
Regeneron Advances First-in-Human Myeloma Combo Trial, Keeping Oncology Pipeline in Focus
23d ago
REGN
Regeneron Shareholders Back Directors, Auditor and Executive Pay
PremiumCompany Announcements
Regeneron Shareholders Back Directors, Auditor and Executive Pay
23d ago
8K
REGN
J&J, Bristol-Myers face negotiation risk under new CMS rule, says RBC Capital
PremiumThe Fly
J&J, Bristol-Myers face negotiation risk under new CMS rule, says RBC Capital
26d ago
BMY
JNJ
Regeneron Tests Weekly Praluent Dosing in New Cholesterol Study: What Investors Should Watch
PremiumCompany Announcements
Regeneron Tests Weekly Praluent Dosing in New Cholesterol Study: What Investors Should Watch
1M ago
REGN
RAPID Real‑World Dupixent Data Could Extend Regeneron and Sanofi’s Asthma Edge
PremiumCompany Announcements
RAPID Real‑World Dupixent Data Could Extend Regeneron and Sanofi’s Asthma Edge
1M ago
REGN
CytomX Therapeutics expands licensing agreement with Regeneron
PremiumThe FlyCytomX Therapeutics expands licensing agreement with Regeneron
1M ago
CTMX
REGN
Regeneron’s CLIO-1 Update: What a Completed Early Lymphoma Trial Means for REGN Investors
Premium
Company Announcements
Regeneron’s CLIO-1 Update: What a Completed Early Lymphoma Trial Means for REGN Investors
1M ago
REGN
Regeneron Steps Into CAR T for Advanced Prostate Cancer With New Phase 1 Trial
Premium
Company Announcements
Regeneron Steps Into CAR T for Advanced Prostate Cancer With New Phase 1 Trial
1M ago
REGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >